Page 216 - 2021_03-Haematologica-web

862
Letters to the Editor
AstraZeneca, Celgene, Gilead, GSK, Hoffman La-Roche, Janssen, Novartis, Pharmacyclics and Sunesis outside the submitted work; has received personal fees from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffman La-Roche, Janssen, Novartis, Pharmacyclics and Sunesis outside the submitted work; has received non-financial support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffman La-Roche, Janssen, Novartis, Pharmacyclics and Sunesis outside the submitted work. CT has received personal fees from AstraZeneca, Gilead, Novartis, Roche, Janssen, Cellectis, Bayer. SdG has nothing to disclose. FZ has nothing to disclose. SdG is
a co-inventor of abemaciclib. PKT is a full-time employee and shareholder of Eli Lilly and Company, the sponsor of the work. SRPK was an employee of Eli Lilly and Company at the time this study was conducted. LL is a full-time employee and stock shareholder of Eli Lilly and Company, the sponsor of the work. LL is a full-time employee and stock shareholder of Eli Lilly and Company, the sponsor of the work. SBu is a full-time employee and stock shareholder of Eli Lilly and Company, the sponsor of the work. SBa is a full-time employee and stock shareholder of Eli Lilly and Company, the sponsor of the work. MMB was a full-time employee and stock shareholder
of Eli Lilly and Company, the sponsor of the work. MW has nothing to disclose. Dr. Hess has received grants from Pfizer, Celgene, Roche and Morphosys; has received personal feels from Janssen, Celgene, Roche, Gilead, Morphsys and Novartis outside the submitted work.
Contributions: FM, FZ, LMG conceived the work; FM, LL designed the work; FM, KB, SS, CT, SDG, FZ, PKT, MW, GH acquired data for the work; FM, SS, CT, PKT, SRPK, LL, LQL, SB, SB analyzed data for the work; FM, MB, SS, CT, PKT, LQL, SB, MW,GH, SB interpreted data for the work; SDG, LMG, PKT, SRPK, SB drafted the work; FM, KB, SS, CT, FZ, PKT, LL, LQL, SB, MB, MW, GH, SB critically revised the work.
Acknowledgments: the authors thank the investigators and staff who conducted this study, and the patients and their families for their partici- pation. Nirmala Xavier, employee of Eli Lilly and Company, provided medical writing support for this manuscript.
Funding: this study was funded by Eli Lilly and company.
References
1. Arora PC, Portell CA. Novel therapies for relapsed/refractory mantle cell lymphoma. Best Pract Res Clin Haematol. 2018;31(1):105-113. 2. Gong X, Litchfield LM, Webster Y, et al. Genomic aberrations that
activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib. Cancer Cell. 2017;32(6):761-776.
3. Dempsey JA, Chan EM, Burke TF, Beckmann RP. Abstract LB-122: LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer. Cancer Res. 2013;73(8 Suppl):LB-122.
4. Martin P, Bartlett NL, Blum KA, et al. A phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133(11):1201-1204.
5. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lym- phomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244-1253.
6. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lym- phoma. J Clin Oncol. 2006;24(30):4867-4874.
7. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688-3695.
8. Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lym- phoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799-1803.
9. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refrac- tory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659-667.
10. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
11. Zhao X, Lwin T, Silva A, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.
12. Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211-1223.
13. Chiron D, Di Liberto M, Martin P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lym- phoma. Cancer Discov. 2014;4(9):1022-1035.
14. Tate SC, Cai S, Ajamie RT, et al. Semi-mechanistic pharmacokinet- ic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. Clin Cancer Res. 2014;20(14): 3763-3774.
15. Burke T, Torres R, McNulty A, et al. Abstract 2830: The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6. Cancer Res. 2016;76(14 Suppl):2830.
haematologica | 2021; 106(3)